KR950700779A - 단백질의 정제방법(Protein purification) - Google Patents

단백질의 정제방법(Protein purification)

Info

Publication number
KR950700779A
KR950700779A KR1019940703342A KR19940703342A KR950700779A KR 950700779 A KR950700779 A KR 950700779A KR 1019940703342 A KR1019940703342 A KR 1019940703342A KR 19940703342 A KR19940703342 A KR 19940703342A KR 950700779 A KR950700779 A KR 950700779A
Authority
KR
South Korea
Prior art keywords
purification method
protein purification
purification
application
relates
Prior art date
Application number
KR1019940703342A
Other languages
English (en)
Other versions
KR100241172B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700779A publication Critical patent/KR950700779A/ko
Application granted granted Critical
Publication of KR100241172B1 publication Critical patent/KR100241172B1/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019940703342A 1992-03-24 1993-03-24 단백질의 정제 방법 KR100241172B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/857,022 US5252216A (en) 1992-03-24 1992-03-24 Protein purification
US07/857,022 1992-03-24
PCT/US1993/002732 WO1993018835A1 (en) 1992-03-24 1993-03-24 Protein purification

Publications (2)

Publication Number Publication Date
KR950700779A true KR950700779A (ko) 1995-02-20
KR100241172B1 KR100241172B1 (ko) 2000-02-01

Family

ID=25324998

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703342A KR100241172B1 (ko) 1992-03-24 1993-03-24 단백질의 정제 방법

Country Status (19)

Country Link
US (1) US5252216A (ko)
EP (1) EP0643608B1 (ko)
JP (1) JP3335629B2 (ko)
KR (1) KR100241172B1 (ko)
AT (1) ATE193839T1 (ko)
AU (1) AU659936B2 (ko)
CA (1) CA2132533C (ko)
DE (1) DE69328864T2 (ko)
DK (1) DK0643608T3 (ko)
ES (1) ES2149206T3 (ko)
FI (1) FI109202B (ko)
GR (1) GR3034332T3 (ko)
MX (1) MX9301655A (ko)
NO (1) NO310855B1 (ko)
NZ (1) NZ251601A (ko)
PT (1) PT643608E (ko)
TW (1) TW321651B (ko)
WO (1) WO1993018835A1 (ko)
ZA (1) ZA932015B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
CN1130353A (zh) * 1993-07-09 1996-09-04 史密丝克莱恩比彻姆公司 蛋白质的纯化
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
EP0835446B1 (en) * 1995-06-26 2003-04-09 Perseptive Biosystems, Inc. High speed, automated, continuous flow, multi-dimensional molecular selection and analysis
EP1300679A3 (en) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Molecular selection and analysis
GB9515196D0 (en) * 1995-07-25 1995-09-20 Matthey Rustenburg Refines Interseparation of platignum group metals
WO1999000168A1 (en) * 1997-06-27 1999-01-07 Life Technologies, Inc. One step device and process for concentration and purification of biological molecules
US5993653C1 (en) * 1997-08-11 2001-11-06 Phenomenex Composition and column used in hplc
US6869796B2 (en) * 1997-08-26 2005-03-22 Avaris Ab Method of introducing organic molecules into target cells
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US6855263B2 (en) * 2002-07-23 2005-02-15 Nuvue Technologies, Inc. Rapid process for purification and concentration of plasmin
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US6913695B2 (en) * 2003-07-08 2005-07-05 Bayer Healthcare Llc Sanitization of chromatographic media
WO2005012349A2 (en) * 2003-08-01 2005-02-10 Lorantis Limited Chromatographic process for the purification of notch ligands
US7329353B2 (en) * 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
DE602005016818D1 (de) * 2004-07-20 2009-11-05 Symphogen As Verfahren zur charakterisierung einer polyklonalen zellinie
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
JP5026266B2 (ja) * 2004-08-12 2012-09-12 リポクセン テクノロジーズ リミテッド 分別
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
WO2007053235A1 (en) * 2005-11-04 2007-05-10 Sachem, Inc. Cation-exchange displacement chromatography process and cationic organic compounds for use as displacer compounds in cation-exchange displacement chromatography process
CA3148917A1 (en) 2006-03-08 2007-09-13 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2010101865A1 (en) 2009-03-02 2010-09-10 Zymo Research Corporation Universal column
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
CN107661491A (zh) 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2023240322A1 (en) * 2022-06-17 2023-12-21 CSL Innovation Pty Ltd Purification of soluble complement receptor and variants thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319495C2 (de) * 1973-04-17 1985-01-10 Yeda Research And Development Co., Ltd., Rehovot Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5159063A (en) * 1989-02-02 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a 120 kda glycoprotein plasma
US5030352A (en) * 1990-01-25 1991-07-09 Purdue Research Foundation Coated media for chromatography

Also Published As

Publication number Publication date
DE69328864D1 (de) 2000-07-20
TW321651B (ko) 1997-12-01
WO1993018835A1 (en) 1993-09-30
FI109202B (fi) 2002-06-14
NO943546D0 (no) 1994-09-23
ES2149206T3 (es) 2000-11-01
ATE193839T1 (de) 2000-06-15
GR3034332T3 (en) 2000-12-29
DK0643608T3 (da) 2000-10-02
NO310855B1 (no) 2001-09-10
FI944412A (fi) 1994-09-23
JPH07505469A (ja) 1995-06-15
NO943546L (no) 1994-11-23
MX9301655A (es) 1994-03-31
CA2132533A1 (en) 1993-09-30
US5252216A (en) 1993-10-12
AU659936B2 (en) 1995-06-01
NZ251601A (en) 1997-03-24
ZA932015B (en) 1994-09-21
AU3932493A (en) 1993-10-21
JP3335629B2 (ja) 2002-10-21
KR100241172B1 (ko) 2000-02-01
FI944412A0 (fi) 1994-09-23
EP0643608B1 (en) 2000-06-14
CA2132533C (en) 2004-01-13
EP0643608A4 (en) 1997-11-26
EP0643608A1 (en) 1995-03-22
DE69328864T2 (de) 2000-12-14
PT643608E (pt) 2000-11-30

Similar Documents

Publication Publication Date Title
KR950700779A (ko) 단백질의 정제방법(Protein purification)
DK0746398T3 (da) Antistofrensning
EE9900492A (et) II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud
DK174484A (da) Fremgangsmaade til chromatografisk fraktionering af plasmaproteiner
DE69430016D1 (de) Proteinreinigung
DK0538754T3 (da) Anvendelse af antistofholdige præparater til immunundertrykkelse
ES2117624T3 (es) Peptidos anticoagulantes.
DE68928942T2 (de) Antikoagulierende Peptide
DE69122103T2 (de) Antigerinnungspeptide
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021024

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee